Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against GoHealth, Inc. and Abacus Global Management, Inc. for possible violations of federal securities laws and unlawful business practices [1] GoHealth, Inc. (NASDAQ:GOCO) - The U.S. Department of Justice filed a False Claims Act complaint against GoHealth and other health insurance companies, alleging that from 2016 to at least 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [2] - Following the DOJ's announcement, GoHealth's stock price dropped by $1.09 per share, a decline of 10.35%, closing at $9.44 per share on May 1, 2025 [2] Abacus Global Management, Inc. (NASDAQ:ABL) - Morpheus Research published a report alleging that Abacus Global Management is involved in an accounting scheme related to life settlements, which artificially inflates revenue by underestimating mortality rates [3] - In response to the report, Abacus Global's stock price fell by more than 21% [3]

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Abacus Global investigation or if you are an Abacus Global investor who suff ...

Core Viewpoint - Abacus Global Management has authorized a $20 million share repurchase program, reflecting confidence in its business model and balance sheet amidst a short attack on its stock price [1][2]. Group 1: Share Repurchase Program - The share repurchase program is effective from June 5, 2025, and will last for up to 18 months [1]. - The company may repurchase shares through various methods, including open market transactions and block trades, at its discretion based on several factors [2]. - The program is expected to be funded using cash on hand and anticipated future free cash flow [2]. Group 2: Management's Response - The CEO of Abacus stated that the current depressed share price presents a buying opportunity, supported by the new share repurchase program and employee investments totaling over $2 million [2]. - The company is committed to pursuing legal action against those responsible for the short attack [3]. Group 3: Company Overview - Abacus Global Management specializes in alternative asset management, data-driven wealth solutions, and technology innovations, focusing on longevity-based assets and personalized financial planning [8].

Company Overview - Abacus Global Management, Inc. operates as an alternative asset manager and market maker [3] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1] - The investigation follows a report published by Morpheus Research, which accused Abacus Global of engaging in an accounting scheme related to life settlements, leading to a significant drop in stock price [3] Market Reaction - Following the publication of the Morpheus Research report, Abacus Global's stock price fell by more than 21% [3]

Core Insights - Holzer & Holzer, LLC is investigating Abacus Global Management, Inc. for potential violations of federal securities laws following a report by Morpheus Research alleging that the company's returns are artificially inflated through questionable accounting practices [1] - The report claims that Abacus employs a "mark to model" accounting scheme that resembles past failures in the life settlements industry, leading to a decline in the company's stock price [1] Company Overview - Abacus Global Management, Inc. is publicly traded on NASDAQ under the ticker ABL [1] - The company is currently facing scrutiny due to allegations of asset overvaluation and non-compliance with securities regulations [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, with a history of representing shareholders and recovering significant amounts for those affected by corporate misconduct [3] - The firm has been recognized as a top-rated securities litigation law firm for the years 2021, 2022, and 2023 [3]

ORLANDO, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, today provided the following response to a false and misleading short attack. Abacus has been buying and selling life insurance policies for over two decades with long-standing and trusted counter-party relationships. If Abacus used flawed data causing over-valuation of the underlying insurance product assets, the Company would be goin ...

Group 1 - Abacus Global Management, Inc. is under investigation for potential securities law violations following a report by Morpheus Research alleging the company is generating fake revenue through aggressive accounting practices [2][4]. - The company's shares fell over 15% in intraday trading on June 4, 2025, due to the allegations of using internal life expectancy estimates that understate insured individuals' lifespans [2]. - The report also highlights undisclosed related-party transactions and significant policy markups exceeding 80% shortly after purchase [2]. Group 2 - Block & Leviton is actively investigating Abacus Global Management and may file an action to recover losses for investors who have been affected [4]. - Investors who have lost money on their Abacus investments are encouraged to contact Block & Leviton for potential recovery options [5]. - The firm is recognized as a leading securities class action firm, having recovered billions for defrauded investors [7].

Core Viewpoint - Abacus Life, Inc. (ABL) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2025, Abacus Life, Inc. is projected to earn $0.76 per share, reflecting a 15.2% increase from the previous year, with a 2% rise in the Zacks Consensus Estimate over the past three months [8]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of Abacus Life, Inc. to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Abacus Life, Inc. (ABL) shares have increased by 7.5% recently, with a mean price target of $13.70 suggesting a potential upside of 57.5% from the current price of $8.70 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.10, indicating variability among analysts [2] - The lowest price target of $12 suggests a 37.9% increase, while the highest target of $15 indicates a potential surge of 72.4% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ABL's earnings prospects, as indicated by upward revisions in EPS estimates, which correlate with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 1% over the past month, reflecting two upward revisions and one downward revision [12] - ABL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]

Company Performance - Abacus Life, Inc. (ABL) has gained approximately 11.1% year-to-date, outperforming the average gain of 4.6% in the Finance group [4] - The Zacks Consensus Estimate for ABL's full-year earnings has increased by 2% over the past 90 days, indicating improving analyst sentiment [4] - Abacus Life, Inc. currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook for the stock [3] Industry Context - Abacus Life, Inc. is part of the Insurance - Life Insurance industry, which consists of 16 individual stocks and is currently ranked 75 in the Zacks Industry Rank [6] - The Insurance - Life Insurance industry has seen an average gain of 1.6% year-to-date, indicating that ABL is performing better than its peers in this specific sector [6] - In contrast, the REIT and Equity Trust industry, to which Annaly Capital Management (NLY) belongs, is ranked 155 and has declined by 2.7% this year [6]